Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles.

Dormont F, Rouquette M, Mahatsekake C, Gobeaux F, Peramo A, Brusini R, Calet S, Testard F, Lepetre-Mouelhi S, Desmaële D, Varna M, Couvreur P.

J Control Release. 2019 Aug 10;307:302-314. doi: 10.1016/j.jconrel.2019.06.040. Epub 2019 Jun 29.


Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules.

Boissenot T, Bordat A, Larrat B, Varna M, Chacun H, Paci A, Poinsignon V, Fattal E, Tsapis N.

J Control Release. 2017 Oct 28;264:219-227. doi: 10.1016/j.jconrel.2017.08.041. Epub 2017 Sep 1.


Gold nanoparticles in cardiovascular imaging.

Varna M, Xuan HV, Fort E.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jan;10(1). doi: 10.1002/wnan.1470. Epub 2017 Apr 6. Review.


Nanomedicine as a strategy to fight thrombotic diseases.

Varna M, Juenet M, Bayles R, Mazighi M, Chauvierre C, Letourneur D.

Future Sci OA. 2015 Nov 1;1(4):FSO46. doi: 10.4155/fso.15.46. eCollection 2015 Nov. Review.


Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma.

Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Mazouz Dorval S, Dumaz N, Janin A, Mourah S, Lebbé C.

Oncotarget. 2016 Jul 26;7(30):48850. doi: 10.18632/oncotarget.10822. No abstract available.


Validation of a preclinical model for assessment of drug efficacy in melanoma.

Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Dorval SM, Dumaz N, Soulie J, Janin A, Mourah S, Lebbé C.

Oncotarget. 2016 Mar 15;7(11):13069-81. doi: 10.18632/oncotarget.7541. Erratum in: Oncotarget. 2016 Jul 26;7(30):48850. Soulie, J [added].


Nanomedicine for the molecular diagnosis of cardiovascular pathologies.

Juenet M, Varna M, Aid-Launais R, Chauvierre C, Letourneur D.

Biochem Biophys Res Commun. 2015 Dec 18;468(3):476-84. doi: 10.1016/j.bbrc.2015.06.138. Epub 2015 Jun 27. Review.


Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma.

Bousquet G, El Bouchtaoui M, Leboeuf C, Battistella M, Varna M, Ferreira I, Plassa LF, Hamdan D, Bertheau P, Feugeas JP, Damotte D, Janin A.

Oncotarget. 2015 Aug 7;6(22):19279-89.


Stem cells increase in numbers in perinecrotic areas in human renal cancer.

Varna M, Gapihan G, Feugeas JP, Ratajczak P, Tan S, Ferreira I, Leboeuf C, Setterblad N, Duval A, Verine J, Germain S, Mongiat-Artus P, Janin A, Bousquet G.

Clin Cancer Res. 2015 Feb 15;21(4):916-24. doi: 10.1158/1078-0432.CCR-14-0666. Epub 2014 Dec 11.


Detection of plasmonic nanoparticles with full field-OCT: optical and photothermal detection.

Nahas A, Varna M, Fort E, Boccara AC.

Biomed Opt Express. 2014 Sep 11;5(10):3541-6. doi: 10.1364/BOE.5.003541. eCollection 2014 Oct 1.


Stability of preclinical models of aggressive renal cell carcinomas.

Varna M, Bousquet G, Ferreira I, Goulard M, El-Bouchtaoui M, Artus PM, Verine J, de Kerviler E, Hernandez L, Leboeuf C, Escudier B, Legrès L, Setterblad N, Soliman H, Feugeas JP, Janin A, Bertheau P.

Int J Clin Exp Pathol. 2014 May 15;7(6):2950-62. eCollection 2014.


Assessment of chimerism in epithelial cancers in transplanted patients.

Leboeuf C, Ratajczak P, Vérine J, Elbouchtaoui M, Plassa F, Legrès L, Ferreira I, Sandid W, Varna M, Bousquet G, Verneuil L, Janin A.

Pathobiology. 2014;81(3):114-22. doi: 10.1159/000357621. Epub 2014 Mar 8. Review.


p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.


Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

Bousquet G, Varna M, Ferreira I, Wang L, Mongiat-Artus P, Leboeuf C, de Bazelaire C, Faivre S, Bertheau P, Raymond E, Germain S, Janin A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1183-93. doi: 10.1007/s00280-013-2300-0. Epub 2013 Sep 24.


Human skin carcinoma arising from kidney transplant-derived tumor cells.

Verneuil L, Varna M, Ratajczak P, Leboeuf C, Plassa LF, Elbouchtaoui M, Schneider P, Sandid W, Lebbé C, Peraldi MN, Sigaux F, de Thé H, Janin A.

J Clin Invest. 2013 Sep;123(9):3797-801. doi: 10.1172/JCI66721. Epub 2013 Aug 27.


Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy.

Huang L, Perrault C, Coelho-Martins J, Hu C, Dulong C, Varna M, Liu J, Jin J, Soria C, Cazin L, Janin A, Li H, Varin R, Lu H.

J Hematol Oncol. 2013 Jul 9;6:49. doi: 10.1186/1756-8722-6-49.


Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, Espié M, de Kerviler E, de Bazelaire C.

Eur Radiol. 2013 Sep;23(9):2420-31. doi: 10.1007/s00330-013-2850-x. Epub 2013 May 8.


Human de novo papillary renal-cell carcinomas in a kidney graft: evidence of recipient origin with adenoma-carcinoma sequence.

Verine J, Varna M, Ratajczak P, El-Bouchtaoui M, Leboeuf C, Plassa LF, Soliman H, Sandid W, Abboud I, Bousquet G, Verneuil L, Peraldi MN, Mongiat-Artus P, Janin A.

Am J Transplant. 2013 Apr;13(4):984-992. doi: 10.1111/ajt.12163. Epub 2013 Feb 20.


Donor-derived keratinocytes in actinic keratosis and squamous cell carcinoma in patients with kidney transplant.

Verneuil L, Varna M, Leboeuf C, Plassa LF, Elbouchtaoui M, Loisel-Ferreira I, Bouhidel F, Peraldi MN, Lebbé C, Ratajczak P, Janin A.

J Invest Dermatol. 2013 Apr;133(4):1108-11. doi: 10.1038/jid.2012.422. Epub 2012 Nov 29. No abstract available.


Necrosis assessment in renal carcinoma.

de Bazelaire C, Rivet J, Varna M, Katsahian S, Leboeuf C, Sandid W, Bertheau P, Janin A.

Hum Pathol. 2012 Jan;43(1):150-1; author reply 151-2. doi: 10.1016/j.humpath.2011.09.005. No abstract available.


TP53 status and response to treatment in breast cancers.

Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A.

J Biomed Biotechnol. 2011;2011:284584. doi: 10.1155/2011/284584. Epub 2011 May 9. Review.


Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P.

Br J Cancer. 2011 May 24;104(11):1739-46. doi: 10.1038/bjc.2011.135. Epub 2011 May 3.


Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL.

Haematologica. 2011 Jun;96(6):927-31. doi: 10.3324/haematol.2010.037689. Epub 2011 Feb 17.


[Mechanisms of resistance to inhibitors of the VEGF pathway].

Bousquet G, Varna M, Janin A.

Ann Pathol. 2010 Nov;30(5 Suppl 1):40-1. doi: 10.1016/j.annpat.2010.07.032. Epub 2010 Sep 16. French. No abstract available.


Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.

Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L, Chen L, Shen ZX, Lu H, Zhao WL, Janin A.

J Hematol Oncol. 2010 Sep 9;3:30. doi: 10.1186/1756-8722-3-30.


Epstein-Barr virus involvement in the pathogenesis of hydroa vacciniforme: an assessment of seven adult patients with long-term follow-up.

Verneuil L, Gouarin S, Comoz F, Agbalika F, Creveuil C, Varna M, Vabret A, Janin A, Leroy D.

Br J Dermatol. 2010 Jul;163(1):174-82. doi: 10.1111/j.1365-2133.2010.09789.x. Epub 2010 Mar 29.


The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.

Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Oct 1;8(19):3172-81. Epub 2009 Oct 4.


Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E.

Cancer Res. 2009 May 15;69(10):4260-9. doi: 10.1158/0008-5472.CAN-08-2837. Epub 2009 May 5.


Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation.

Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legrès L, Desveaux A, Varna M, Ratajczak P, Soulier J, de Thé H, Bertheau P, Socié G.

Blood. 2009 Feb 19;113(8):1834-40. doi: 10.1182/blood-2008-07-171702. Epub 2008 Dec 5.


p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P.

Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049.


TP53 status and response to chemotherapy in breast cancer.

Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thé H.

Pathobiology. 2008;75(2):132-9. doi: 10.1159/000123851. Epub 2008 Jun 10. Review.


Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.

Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legrès L, Plassa LF, de Roquancourt A, Espié M, Misset JL, Janin A, de Thé H, Bertheau P.

Br J Cancer. 2007 Oct 22;97(8):1157-64. Epub 2007 Sep 18.


Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.

Supplemental Content

Support Center